Natera/$NTRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
$NTRA
Sector
Primary listing
Employees
4,429
Headquarters
Website
Natera Metrics
BasicAdvanced
$24B
-
-$1.92
1.68
-
Price and volume
Market cap
$24B
Beta
1.68
52-week high
$183.00
52-week low
$117.27
Average daily volume
1.3M
Financial strength
Current ratio
3.72
Quick ratio
3.444
Long term debt to equity
8.244
Total debt to equity
14.691
Interest coverage (TTM)
-45.40%
Profitability
EBITDA (TTM)
-262.661
Gross margin (TTM)
62.86%
Net profit margin (TTM)
-12.89%
Operating margin (TTM)
-14.95%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-11.21%
Return on equity (TTM)
-24.32%
Valuation
Price to revenue (TTM)
11.536
Price to book
18.89
Price to tangible book (TTM)
18.89
Price to free cash flow (TTM)
216.716
Free cash flow yield (TTM)
0.46%
Free cash flow per share (TTM)
0.794
Growth
Revenue change (TTM)
44.38%
Earnings per share change (TTM)
-21.26%
3-year revenue growth (CAGR)
39.51%
10-year revenue growth (CAGR)
26.40%
3-year earnings per share growth (CAGR)
-31.80%
10-year earnings per share growth (CAGR)
-9.92%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Bulls say / Bears say
Q2 2025 revenue rose 32.2% year-over-year to $546.6 million, driven by strong demand across its oncology, women’s health, and organ health franchises (Reuters)
Test volumes increased 12.2% year-over-year in Q2 2025, including a 50.6% surge in oncology tests, underscoring accelerating adoption of the Signatera MRD assay (Reuters)
Gross margin expanded to 63.4% in Q2 2025 from 58.8% a year ago, benefiting from cost efficiencies and incremental cash true-ups (Reuters)
Net loss widened to $100.9 million in Q2 2025 from $37.5 million a year earlier, putting pressure on EPS at ($0.74) per share (Reuters)
Operating expenses rose sharply to $457 million in Q2 2025, up 59.2% year-over-year, undermining profitability in spite of strong revenue growth (Reuters)
Natera faces a trade-secret lawsuit from Guardant Health filed in February 2025, alleging theft of confidential files and introducing legal risk and potential liabilities (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Natera News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Natera stock?
Natera (NTRA) has a market cap of $24B as of September 16, 2025.
What is the P/E ratio for Natera stock?
The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of September 16, 2025.
Does Natera stock pay dividends?
No, Natera (NTRA) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Natera dividend payment date?
Natera (NTRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Natera?
Natera (NTRA) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.